

# CITATION REPORT

List of articles citing

**Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia**

**DOI: 10.1016/j.ejim.2020.05.009**

**European Journal of Internal Medicine, 2020, 76, 31-35.**

**Source:** <https://exaly.com/paper-pdf/76687011/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
211	Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression. <b>2020</b> , 9,		57
210	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. <b>2020</b> , 20, 1-112		2
209	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. <b>2020</b> , 80, 1929-1946		45
208	Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis. <b>2020</b> , 7, 586221		30
207	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <b>2020</b> , 18, 405		64
206	Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. <b>2020</b> , 89, 107102		19
205	Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?. <b>2020</b> , 2, e779-e790		43
204	Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. <b>2020</b> , 89, 107018		34
203	Reply to Olivera and Mallat. <b>2021</b> , 73, e272-e273		
202	Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. <b>2020</b> , 114, 102523		38
201	Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. <b>2021</b> , 73, e445-e454		235
200	Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. <b>2020</b> , 11, 1439		16
199	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. <b>2020</b> , 2, 1-12		11
198	The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. <b>2020</b> , 257, 118097		36
197	Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?. <b>2020</b> , 7, 571597		5
196	Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. <b>2021</b> , 72, e1130-e1143		14
195	Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches. <b>2020</b> , 48, 1841-1844		35

194	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. <b>2020</b> , 7, 2054358120967845	9
193	Management of Canadian Pediatric Patients With Glomerular Diseases During the COVID-19 Pandemic: Recommendations From the Canadian Association of Pediatric Nephrologists COVID-19 Rapid Response Team. <b>2020</b> , 7, 2054358120970713	2
192	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. <b>2020</b> , 11, 588409	11
191	Tratamientos farmacológicos de los pacientes con COVID19: interacciones e indicaciones. <b>2020</b> , 20, 33-39	
190	Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients. <b>2020</b> , 117, 30898-30899	
189	Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?. <b>2020</b> , 8, 677	30
188	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. <b>2020</b> , 72, 1791-1805	184
187	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. <b>2020</b> , 180, 114169	19
186	Tocilizumab for severe COVID-19: a systematic review and meta-analysis. <b>2020</b> , 56, 106103	104
185	Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. <b>2020</b> , 26, 1983-1994	26
184	Targeting IL-6 in COVID-19. Response to: Rational use of tocilizumab in COVID-19sby Jain and Sharma. <b>2020</b> ,	1
183	[Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia]. <b>2020</b> , 155, 548-556	27
182	Can tocilizumab calm the cytokine storm of COVID-19?. <b>2020</b> , 2, e449-e451	6
181	Immunosuppressive Drugs and COVID-19: A Review. <b>2020</b> , 11, 1333	48
180	Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. <b>2020</b> , 99, 491-495	37
179	Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: Colchicine treatment in community healthcare setting to prevent severe COVID-19sby Della-Torre. <b>2020</b> ,	4
178	How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. <b>2020</b> , 25, 37	3
177	The role of Interleukin 6 inhibitors in therapy of severe COVID-19. <b>2020</b> , 131, 110698	46

176	When two for the price of one isn't a bargain: estimating prevalence and microbiology of bacterial co-infections in patients with COVID-19. <b>2020</b> , 26, 1602-1603	8
175	Is there any potential management against COVID-19? A systematic review and meta-analysis. <b>2020</b> , 28, 765-777	9
174	Efficacy of various treatment modalities for nCoV-2019: A systematic review and meta-analysis. <b>2020</b> , 50, e13383	12
173	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <b>2020</b> , 15, e0237831	62
172	Pharmacological treatments of COVID-19. <b>2020</b> , 72, 1446-1478	16
171	Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona. <b>2020</b> , 15, e0237960	53
170	A Narrative Review of Emerging Therapeutics for COVID-19. <b>2020</b> , 4, 745-758	5
169	Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients. <b>2020</b> , 23, 1030-1039	8
168	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. <b>2020</b> , 11, 584956	30
167	Effects of Tocilizumab in COVID-19 patients: a cohort study. <b>2020</b> , 20, 964	17
166	Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of gene polymorphisms in novel coronavirus pneumonia. <b>2020</b> , 155, 548-556	8
165	Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study. <b>2020</b> , 38, 117-123	14
164	NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19. <b>2020</b> , 11, 570251	32
163	Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. <b>2020</b> , 46, 102592	2
162	Tocilizumab and liver injury in patients with COVID-19. <b>2020</b> , 13, 1756284820959183	13
161	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. <b>2020</b> , 9,	29
160	Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 76, 21-22	3.9 14
159	Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced PANICSttack. <b>2020</b> , 415, 116935	24

158	Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. <b>2020</b> , 113, 546-550	86
157	Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. <b>2020</b> , 24, 100418	113
156	NK cells: A double edge sword against SARS-CoV-2. <b>2020</b> , 77, 100737	44
155	Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. <b>2020</b> , 11, 1626	74
154	Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). <b>2020</b> , 75, 2445-2476	81
153	SARS-CoV-2 pandemic: An overview. <b>2020</b> , 77, 100736	30
152	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. <b>2020</b> , 40, 1353-1360	19
151	Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm. <b>2021</b> , 93, 120-121	2
150	Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Anti-inflammatory Therapy for Severe Coronavirus Disease (COVID). <b>2021</b> , 72, 1682-1683	11
149	Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. <b>2021</b> , 19, 93-100	21
148	Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. <b>2021</b> , 289, 434-436	41
147	Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. <b>2021</b> , 27, 52-66	69
146	Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies. <b>2021</b> , 72, e742-e749	54
145	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. <b>2021</b> , 181, 41-51	213
144	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. <b>2021</b> , 41, 303-314	27
143	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review. <b>2021</b> , 19, 679-687	8
142	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. <b>2021</b> , 73, e13-e29	149
141	Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope. <b>2021</b> , 90, 107156	3

140	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. <b>2021</b> , 93, 2270-2280		20
139	Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 83, 34-38	3.9	14
138	Repurposed Tocilizumab in Patients with Severe COVID-19. <b>2021</b> , 206, 599-606		11
137	Tocilizumab in the Management of COVID-19: A Preliminary Report. <b>2021</b> , 361, 208-215		5
136	What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies. <b>2021</b> , 56, 217-221		1
135	Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. <b>2021</b> , 77, 311-319		19
134	Potential role of subcutaneous tocilizumab injections in patients with COVID-19 associated pneumonia. <b>2021</b> , 93, 686-688		1
133	Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis. <b>2021</b> , 93, 1620-1630		52
132	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). <b>2021</b> , 27, 244-252		61
131	Efficacy and safety of tocilizumab in the management of COVID-19: A systematic review and meta-analysis of observational studies.		
130	Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. <b>2021</b> , 16, 843-852		18
129	Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study. <b>2021</b> , 17, 2124-2134		2
128	The Novel Coronavirus and Inflammation. <b>2021</b> , 1321, 127-138		3
127	Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm. <b>2021</b> , 11,		28
126	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. <b>2021</b> , 93, 2694-2704		9
125	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. <b>2020</b> , 11, 583914		4
124	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.		
123	Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19. <b>2021</b> , 25, 908-916		4

122	Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis. <b>2021</b> , 10, 73	9
121	CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. <b>2021</b> , 26, 515-525	7
120	Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. <b>2021</b> , 76, 907-919	49
119	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. <b>2021</b> , 22, 275-296	56
118	The Rheumatology Drugs for COVID-19 Management: Which and When?. <b>2021</b> , 10,	8
117	Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials.	
116	"Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience", a retrospective study-original article. <b>2021</b> , 63, 102165	5
115	Coronavirus disease 2019 (COVID-19) and autoimmunity. <b>2021</b> , 59, 5-30	18
114	Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion. <b>2021</b> , 9, e0733	2
113	Interleukin-6 Antagonists: Lessons From Cytokine Release Syndrome to the Therapeutic Application in Severe COVID-19 Infection. <b>2021</b> , 8971900211000691	4
112	Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. <b>2021</b> , 53, 559-580	5
111	Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 17, 499-511	12
110	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. <b>2021</b> , 147, 1217-1225	30
109	The role of IL-6 and IL-6 blockade in COVID-19. <b>2021</b> , 17, 601-618	10
108	Impact of tocilizumab on clinical outcomes in severe covid-19 patients and risk of secondary infection: A case-control study.	
107	Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). <b>2021</b> , 35, 1661-1670	7
106	Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. <b>2021</b> , 21, 411	33
105	Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. <b>2021</b> , 10, 71	13

104	Management of patients with severe acute respiratory failure due to SARS-CoV-2 pneumonia with noninvasive ventilatory support outside Intensive Care Unit. <b>2021</b> , 112, 329-337	2
103	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. <b>2021</b> , 11, 95-109	1
102	Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience. <b>2021</b> , 100, e25832	3
101	Mortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19. <b>2021</b> , 57, 158	
100	Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. <b>2021</b> , 51, 890-897	11
99	Successful Treatment of a Critically Ill COVID-19 Patient Using Continuous Renal Replacement Therapy With Enhanced Cytokine Removal and Tocilizumab: A Case Report. <b>2021</b> , 8, 649583	0
98	COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. <b>2021</b> , 232, 1-12	22
97	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. <b>2021</b> , 9,	9
96	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <b>2021</b> , 10, 1837-1885	10
95	What We Learned from COVID-19: From endotheliitis to treatment.	
94	The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2. <b>2021</b> , 121, 705-714	3
93	COVID-19, Acute Lymphoblastic Leukemia, and Down Syndrome: A Short Review and a Case Report. <b>2021</b> , 14, 1031-1039	0
92	Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis. <b>2021</b> , 10, 1677-1698	0
91	Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6 7
90	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India. <b>2021</b> , 100, e26705	3
89	Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab. <b>2021</b> ,	2
88	Compassionate use of anti-IL6 receptor antibodies in critically ill patients with acute respiratory distress syndrome due to SARS-CoV-2. <b>2021</b> , 87, 1080-1090	2
87	Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic. <b>2021</b> , 18,	8



86	Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis. <b>2021</b> , e2295	9
85	The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. <b>2021</b> , 70, 1233-1246	10
84	The role of endotheliitis in COVID-19: Real-world experience of 11 190 patients and literature review for a pathophysiological map to clinical categorisation. <b>2021</b> , 75, e14843	2
83	Tocilizumab in COVID-19: The Cerrahpaş-PREDICT score. <b>2021</b> , 27, 1329-1335	6
82	Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. <b>2021</b> , 1	2
81	How did COVID-19 affect medical and cardiology journals? A pandemic in literature. <b>2021</b> , 22, 840-847	2
80	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. <b>2021</b> , 41, 884-906	7
79	Cytokine Storm and Immunomodulation in COVID-19: a Review. <b>2021</b> , 02,	
78	COVID-19, cytokines, inflammation, and spices: How are they related?. <b>2021</b> , 284, 119201	15
77	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. <b>2021</b> , 18,	5
76	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. <b>2021</b> , 372, n84	186
75	The Role of Convalescent Plasma and Tocilizumab in the Management of COVID-19 Infection: A Cohort of 110 Patients from a Tertiary Care Hospital in Oman. <b>2021</b> , 11, 216-223	0
74	Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis. <b>2021</b> , 71, 265-274	30
73	Drug repurposing and cytokine management in response to COVID-19: A review. <b>2020</b> , 88, 106947	24
72	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <b>2021</b> , 19, 1009-1027	17
71	Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. <b>2021</b> , 8, ofaa598	13
70	A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19.	14
69	Tocilizumab for patients with COVID-19 pneumonia. The TOCIDVID-19 prospective phase 2 trial.	9

68	Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis.	6
67	The Efficacy of IL-6 Inhibitor Tocilizumab in Reducing Severe COVID-19 Mortality: A Systematic Review.	7
66	Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.	1
65	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis.	3
64	Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. <b>2021</b> , 21, 566	28
63	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <b>2020</b> , 22, 290	17
62	Rapid Radiological Worsening and Cytokine Storm Syndrome in COVID-19 Pneumonia. <b>2020</b> , 7, 001822	3
61	Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. <b>2020</b> , 30, 629-644	4
60	Coronavirus disease 2019 in critically ill patients: can we re-program the immune system? A primer for Intensivists. <b>2020</b> , 86, 1214-1233	1
59	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <b>2020</b> , 11, 598308	14
58	Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. <b>2020</b> , 11, 615972	21
57	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. <b>2020</b> , 8, e10322	25
56	Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence. <b>2020</b> , 12, e10869	17
55	Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. <b>2021</b> , 26, 1027-1040	7
54	Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study. <b>2021</b> , 11, 19728	6
53	Immunosuppressant Management in Renal Transplant Patients with COVID-19. <b>2021</b> , 2021, 9318725	0
52	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , <b>2021</b> ,	3.9 2
51	SARS-CoV-2 lethality did not change over time in two Italian Provinces.	2

50	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature.		0
49	Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia. <b>2021</b> , e14997		2
48	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <b>2020</b> , 1, 16		2
47	Reply to Tleyjeh. <b>2021</b> , 72, e1155-e1156		
46	Identification and Development of Therapeutics for COVID-19. <b>2021</b> , e0023321		5
45	Rationale and prognosis of repurposed drugs with risk stratification of COVID-19 patients requiring Oxygen supplementation: A systematic review and meta-analysis.		
44	Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2. <b>2020</b> , 27, 154-156		
43	New coronavirus infection (COVID-19) in children with acute lymphoblastic leukemia. <b>2020</b> , 65, 198-203		2
42	Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-COVID-19.		
41	Tocilizumab in severe COVID-19: A promise fulfilled. <i>European Journal of Internal Medicine</i> , <b>2021</b> ,	3,9	2
40	An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).. <b>2022</b> , 105, 108536		4
39	Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.. <b>2022</b> , 1		2
38	Treatment of MIS-C in Children and Adolescents.. <b>2022</b> , 10, 1-10		4
37	Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection.. <b>2022</b> , 30, 23		0
36	Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.. <b>2022</b> , 17534259211064602		1
35	Clinical investigation of COVID-19 related pneumonia through HRCT chest scan. <b>2022</b> , 8, 28-33		
34	Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients.. <b>2022</b> , 8, e1292		2
33	Identification and Development of Therapeutics for COVID-19. <b>2021</b> ,		

32	Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP).. <b>2022</b> , 14,	2
31	Cholecalciferol level and its impact on COVID-19 patients.. <b>2022</b> , 34, 23	1
30	Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.. <b>2022</b> , 13, 795315	3
29	Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study.. <b>2022</b> , 100228	
28	Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh.. <b>2022</b> , 54, 723-732	1
27	Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence.. <b>2022</b> , 1-11	0
26	Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry.. <b>2022</b> , 1	0
25	Effects of Tocilizumab on Adults With COVID-19 Pneumonia: A Meta-Analysis.. <b>2022</b> , 9, 838904	0
24	Predictors of Mortality Among Hospitalized COVID-19 Patients at a Tertiary Care Hospital in Ethiopia.. <b>2021</b> , 14, 5363-5373	1
23	Multisystem Inflammatory Syndrome in Children. <b>2021</b> ,	
22	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.. <b>2022</b> , 109, 108786	0
21	Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges.. <b>2022</b> , 2022, 4240378	0
20	3D-LC-MS with D Multimethod Option for Fully Automated Assessment of Multiple Attributes of Monoclonal Antibodies Directly from Cell Culture Supernatants.. <b>2022</b> ,	3
19	Image_1.JPEG. <b>2020</b> ,	
18	Image_2.JPEG. <b>2020</b> ,	
17	Table_1.docx. <b>2020</b> ,	
16	Table_1.docx. <b>2020</b> ,	
15	DataSheet_1.pdf. <b>2020</b> ,	

14	datasheet1.docx. <b>2020</b> ,		
13	Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle.. <i>European Journal of Internal Medicine</i> , <b>2022</b> ,	3.9	
12	Biologics in COVID-19 So Far: Systematic Review. <b>2022</b> , 15, 783		○
11	Tocilizumab Treatment Reduces Mortality in Hospitalized Patients With COVID-19: A Retrospective Cohort Study at a New York City Hospital. <i>Infectious Diseases in Clinical Practice</i> , <b>2022</b> , 30,	0.2	○
10	Tocilizumab as a Treatment for Cytokine Storm in COVID-19 Patients: A systematic review. <b>2022</b> , 6,		
9	Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 1103	3.6	○
8	Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. <b>2022</b> , 3,		2
7	Tocilizumab as a breakthrough in the cytokine storm of COVID-19 pneumonia- Case series in the intensive care unit. <b>2022</b> , 9, 382-386		
6	Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. <b>2022</b> , 12, 1456		○
5	Uso de Tocilizumab en pacientes hospitalizados por neumonía por COVID 19. Estudio de cohorte. <b>2022</b> ,		○
4	Medical and chemical efficacy of respiratory physiotherapy and Remdesivir in patients with COVID-19 pneumonia: A systematic review and meta-analysis. <b>2022</b> , 125, 713-720		○
3	Acute liver injury in COVID-19 patients hospitalized in the intensive care unit: Narrative review. 28, 6662-6688		○
2	Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study. <b>2023</b> , 18, e0281111		○
1	Severe COVID-19 Pneumonia in a Three-Year-Old with Congenital Iron and B12 Deficiency Anemia of Unknown Etiology: A Case Report. <b>2023</b> , 10, 616		○